Case 19-2010: A 35-year-old man with adenocarcinoma of the cecum

New England Journal of Medicine

Volumn 362, Issue 25, 2010, Pages 2411-

  Ryan, David P ^a,b   Engelman, Jeffrey A ^a,b   Ferrone, Cristina R ^a,b   Sahani, Dushyant V ^a,b   Lisovsky, Mikhail ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLFOX PROTOCOL; FOLINIC ACID; IFL PROTOCOL; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

ADULT; ARTICLE; BIOPSY; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CASE REPORT; CECUM CARCINOMA; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEFECATION HABIT; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LAPAROTOMY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; ADENOCARCINOMA; CECUM TUMOR; CLINICAL OBSERVATION; CLINICAL STUDY; COLON RESECTION; DIAGNOSIS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METASTASIS; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PERITONEUM PSEUDOMYXOMA; PERITONEUM TUMOR; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY IMAGING;

ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CECAL NEOPLASMS; COLECTOMY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PERITONEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PSEUDOMYXOMA PERITONEI; RAS PROTEINS; WHOLE BODY IMAGING;

EID: 77953921478     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc1003885     Document Type: Article

References (22)

1. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91. (Pubitemid 32623044)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Zbuk K, Sidebotham EL, Bleyer A, La Quaglia MP. Colorectal cancer in young adults. Semin Oncol 2009;36:439-50.
4. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.
5. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM. AJCC cancer staging handbook. 6th ed. New York: Springer, 2002.
6. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008;19:1829-35.
7. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:3379-84.
8. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007;14:128-33.
9. Köhne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
10. Dy GK, Hobday TJ, Nelson G, et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer 2009;8:88-93.
11. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
12. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721-7.
13. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14: 862-70.
14. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
15. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008; 19:577-82. (Pubitemid 351325682)
16. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
17. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
18. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
19. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9: 550-62.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
21. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
22. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med 2008;359:1834-6.